{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:42:20Z","timestamp":1785901340001,"version":"3.56.0"},"publisher-location":"Cham","reference-count":54,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030753924","type":"print"},{"value":"9783030753931","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/7854_2020_205","type":"book-chapter","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T02:01:34Z","timestamp":1612836094000},"page":"385-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacogenetics of Obsessive-Compulsive Disorder: An Evidence-Update"],"prefix":"10.1007","author":[{"given":"Gwyneth","family":"Zai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,7]]},"reference":[{"issue":"1","key":"205_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jcpt.12766","volume":"44","author":"S Abdolhosseinzadeh","year":"2019","unstructured":"Abdolhosseinzadeh S, Sina M, Ahmadiani A, Asadi S, Shams J (2019) Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder. J Clin Pharm Ther 44(1):39\u201348","journal-title":"J Clin Pharm Ther"},{"key":"205_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pmip.2018.10.001","volume":"11-12","author":"E Ahmadipour","year":"2018","unstructured":"Ahmadipour E, Rashidi FS, Ahmadiani A, Asadi S, Shams J (2018) SLC6A4 polymorphisms rs25533 and I425V: association with obsessive-compulsive disorder and its treatment response in Iranian patients. Personalized Med Psychiatry 11-12:23\u201329","journal-title":"Personalized Med Psychiatry"},{"issue":"5","key":"205_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3109\/09540261.2013.825579","volume":"25","author":"CA Altar","year":"2013","unstructured":"Altar CA, Hornberger J, Shewade A, Cruz V, Garrison J, Mrazek D (2013) Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry 25(5):509\u2013533","journal-title":"Int Rev Psychiatry"},{"key":"205_CR4","unstructured":"American Psychiatric Association (APA) (2007) Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA, USA. http:\/\/www.psych.org\/psych_pract\/treatg\/pg\/prac_guide.cfm"},{"issue":"2","key":"205_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","volume":"11","author":"S Bernard","year":"2006","unstructured":"Bernard S, Neville KA, Nguyen AT, Flockhart DA (2006) Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11(2):126\u2013135","journal-title":"Oncologist"},{"issue":"5","key":"205_CR701","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/sj.mp.4000257","volume":"2","author":"EA Billett","year":"1997","unstructured":"Billett EA, Richter MA, King N, Heils A, Lesch KP, Kennedy JL (1997) Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol Psychiatry 2(5):403\u2013406","journal-title":"Mol Psychiatry"},{"issue":"1","key":"205_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/pgs.11.133","volume":"13","author":"EJ Brandl","year":"2012","unstructured":"Brandl EJ, M\u00fcller DJ, Richter MA (2012) Pharmacogenetics of obsessive-compulsive disorders. Pharmacogenomics 13(1):71\u201381","journal-title":"Pharmacogenomics"},{"issue":"2","key":"205_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/tpj.2013.12","volume":"14","author":"EJ Brandl","year":"2013","unstructured":"Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, M\u00fcller DJ, Richter MA (2013) Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 14(2):176\u2013181","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"205_CR702","first-page":"176","volume":"14","author":"EJ Brandl","year":"2014","unstructured":"Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, Richter MA (2014) Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharm J 14(2):176\u2013181","journal-title":"Pharm J"},{"issue":"7","key":"205_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2217\/pgs-2017-0015","volume":"18","author":"JT Brown","year":"2017","unstructured":"Brown JT, Schneiderhan M, Eum S, Bishop JR (2017) Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics 18(7):601\u2013605","journal-title":"Pharmacogenomics"},{"issue":"5","key":"205_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0897190011422873","volume":"24","author":"CF Caley","year":"2011","unstructured":"Caley CF (2011) Interpreting and applying CYP450 genomic test results to psychotropic medications. J Pharm Pract 24(5):439\u2013446","journal-title":"J Pharm Pract"},{"issue":"2","key":"205_CR10","first-page":"43S","volume":"51","author":"Canadian Psychiatric Association (CPA)","year":"2006","unstructured":"Canadian Psychiatric Association (CPA) (2006) Clinical practice guidelines: management of anxiety disorders. Can J Psychiatr 51(2):43S\u201349S","journal-title":"Can J Psychiatr"},{"issue":"5","key":"205_CR703","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4088\/JCP.v68n0512","volume":"68","author":"D Denys","year":"2007","unstructured":"Denys D, Van Nieuwerburge F, Deforce D, Westenberg HG (2007) Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 68(5):747\u2013753","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"205_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z Desta","year":"2002","unstructured":"Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41(12):913\u2013958","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"205_CR704","first-page":"176","volume":"2","author":"D Di Bella","year":"2002","unstructured":"Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L (2002) Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharm J 2(3):176\u2013181","journal-title":"Pharm J"},{"issue":"3","key":"205_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1017\/S1461145712000740","volume":"16","author":"M Dold","year":"2013","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S (2013) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 16(3):557\u2013574","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"205_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/ajmg.b.32184","volume":"162B","author":"C Fabbri","year":"2013","unstructured":"Fabbri C, Di Girolamo G, Serretti A (2013) Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 162B(6):487\u2013520","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"1","key":"205_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.psychres.2014.12.003","volume":"227","author":"NA Fineberg","year":"2015","unstructured":"Fineberg NA, Reghunandanan S, Simpson HB, Phillips KA, Richter MA, Matthews K, Stein DJ, Sareen J, Brown A, Sookman D (2015) Accreditation Task Force of The Canadian Institute for Obsessive Compulsive Disorders. Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res 227(1):114\u2013125","journal-title":"Psychiatry Res"},{"key":"205_CR15","unstructured":"Flockhart DA (2007) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. http:\/\/medicine.iupui.edu\/clinpharm\/ddis\/clinical-table\/. Accessed 10 Jan 2014"},{"issue":"12","key":"205_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1517\/17460441.2013.845553","volume":"8","author":"MA Grados","year":"2013","unstructured":"Grados MA, Specht MW, Sung HM, Fortune D (2013) Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach. Expert Opin Drug Discov 8(12):1515\u20131527","journal-title":"Expert Opin Drug Discov"},{"issue":"36","key":"205_CR17","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.2174\/138161212803523617","volume":"18","author":"K Gvozdic","year":"2012","unstructured":"Gvozdic K, Brandl EJ, Taylor DL, M\u00fcller DJ (2012) Genetics and personalized medicine in antidepressant treatment. Curr Pharm Des 18(36):5853\u20135878","journal-title":"Curr Pharm Des"},{"issue":"2","key":"205_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, M\u00fcller DJ, Li U, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98(2):127\u2013134","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"205_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","volume":"102","author":"JK Hicks","year":"2017","unstructured":"Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, M\u00fcller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC (2017) Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 102(1):37\u201344","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"205_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1515\/DMDI.2000.16.1.39","volume":"16","author":"MW Jann","year":"2000","unstructured":"Jann MW, Cohen LJ (2000) The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact 16(1):39\u201367","journal-title":"Drug Metabol Drug Interact"},{"issue":"1","key":"205_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/YCO.0000000000000017","volume":"27","author":"C Kariuki-Nyuthe","year":"2014","unstructured":"Kariuki-Nyuthe C, Gomez-Mancilla B, Stein DJ (2014) Obsessive-compulsive disorder and the glutamatergic system. Curr Opin Psychiatry 27(1):32\u201337","journal-title":"Curr Opin Psychiatry"},{"issue":"Suppl 1","key":"205_CR22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des troubles anxieux and McGill University (2014) Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 14(Suppl 1):S1","journal-title":"BMC Psychiatry"},{"issue":"2","key":"205_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1586\/ern.09.148","volume":"10","author":"MS Koo","year":"2010","unstructured":"Koo MS, Kim EJ, Roh D, Kim CH (2010) Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Rev Neurother 10(2):275\u2013290","journal-title":"Expert Rev Neurother"},{"issue":"7 Suppl","key":"205_CR24","first-page":"5","volume":"164","author":"LM Koran","year":"2007","unstructured":"Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American Psychiatric Association (2007) Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 164(7 Suppl):5\u201353","journal-title":"Am J Psychiatry"},{"issue":"8","key":"205_CR705","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/ajmg.b.32736","volume":"180","author":"G Lazaro-Munoz","year":"2019","unstructured":"Lazaro-Munoz G, Sabatello M, Huckins L, Peay H, Degenhardt F, Meiser B et al (2019) International society of psychiatric genetics ethics committee: issues facing us. Am J Med Genet B Neuropsychiatr Genet 180(8):543\u2013554","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"4","key":"205_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2659","volume":"33","author":"AJ Lisoway","year":"2018","unstructured":"Lisoway AJ, Zai G, Tiwari AK, Zai CC, Wigg K, Goncalves V, Zhang D, Freeman N, M\u00fcller DJ, Kennedy JL, Richter MA (2018) Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive-compulsive disorder. Hum Psychopharmacol 33(4):e2659","journal-title":"Hum Psychopharmacol"},{"issue":"7","key":"205_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2174\/1570159X15666170320104237","volume":"15","author":"Z Marinova","year":"2017","unstructured":"Marinova Z, Chuang DM, Fineberg N (2017) Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol 15(7):977\u2013995","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"205_CR706","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.mp.4000391","volume":"3","author":"CJ McDougle","year":"1998","unstructured":"McDougle CJ, Epperson CN, Price LH, Gelernter J (1998) Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry 3(3):270\u2013273","journal-title":"Mol Psychiatry"},{"issue":"3","key":"205_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.neubiorev.2007.09.005","volume":"32","author":"L Menzies","year":"2008","unstructured":"Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET (2008) Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 32(3):525\u2013549","journal-title":"Neurosci Biobehav Rev"},{"issue":"2B","key":"205_CR707","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1590\/S0004-282X2011000300003","volume":"69","author":"K Miguita","year":"2011","unstructured":"Miguita K, Cordeiro Q, Shavitt RG, Miguel EC, Vallada H (2011) Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment. Arq Neuropsiquiatr 69(2B):283\u2013287","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"205_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tics.2011.11.003","volume":"16","author":"MR Milad","year":"2012","unstructured":"Milad MR, Rauch SL (2012) Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci 16(1):43\u201351","journal-title":"Trends Cogn Sci"},{"key":"205_CR708","doi-asserted-by":"crossref","unstructured":"Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pesic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM (2020) Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA Psychiatry:e203643. http:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3643","DOI":"10.1001\/jamapsychiatry.2020.3643"},{"issue":"8","key":"205_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/gtmb.2011.0327","volume":"16","author":"DJ M\u00fcller","year":"2012","unstructured":"M\u00fcller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, Lieberman JA, Kennedy JL, Richter MA (2012) The AmpliChip\u00ae CYP450 test and response to treatment in schizophrenia and obsessive-compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet Test Mol Biomarkers 16(8):897\u2013903","journal-title":"Genet Test Mol Biomarkers"},{"key":"205_CR30","unstructured":"National Collaborating Centre for Mental Health (UK) (2006) Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. British Psychological Society, Leicester (NICE Clinical Guidelines, No. 31.) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK56458\/"},{"issue":"5-6","key":"205_CR31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/10937400903158342","volume":"12","author":"P Neafsey","year":"2009","unstructured":"Neafsey P, Ginsberg G, Hattis D, Sonawane B (2009) Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 12(5-6):334\u2013361","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"2","key":"205_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.31887\/DCNS.2010.12.2\/dpauls","volume":"12","author":"DL Pauls","year":"2010","unstructured":"Pauls DL (2010) The genetics of obsessive-compulsive disorder: a review. Dialogues Clin Neurosci 12(2):149\u2013163","journal-title":"Dialogues Clin Neurosci"},{"issue":"6","key":"205_CR33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrn3746","volume":"15","author":"DL Pauls","year":"2014","unstructured":"Pauls DL, Abramovitch A, Rauch SL, Geller DA (2014) Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci 15(6):410\u2013424","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"205_CR709","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.biopsych.2009.05.017","volume":"66","author":"E Real","year":"2009","unstructured":"Real E, Gratac\u00f2s M, Soria V, Escaram\u00eds G et al (2009) A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol Psychiatry 66(7):674\u2013680","journal-title":"Biol Psychiatry"},{"issue":"1","key":"205_CR710","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuron.2019.01.046","volume":"102","author":"TW Robbins","year":"2019","unstructured":"Robbins TW, Vaghi MM, Banca P (2019) Obsessive-compulsive disorder: puzzles and prospects. Neuron 102(1):27\u201347","journal-title":"Neuron"},{"issue":"2","key":"205_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/mp.2015.32","volume":"21","author":"H Qin","year":"2016","unstructured":"Qin H, Samuels JF, Wang Y, Zhu Y, Grados MA, Riddle MA, Greenberg BD, Knowles JA, Fyer AJ, McCracken JT, Murphy DL, Rasmussen SA, Cullen BA, Piacentini J, Geller D, Stewart SE, Pauls D, Bienvenu OJ, Goes FS, Maher B, Pulver AE, Valle D, Lange C, Mattheisen M, McLaughlin NC, Liang KY, Nurmi EL, Askland KD, Nestadt G, Shugart YY (2016) Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol Psychiatry 21(2):270\u2013276","journal-title":"Mol Psychiatry"},{"key":"205_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/YCO.0000000000000023","volume":"27","author":"AB Singh","year":"2014","unstructured":"Singh AB, Bousman CA, Ng C, Berk M (2014) Antidepressant pharmacogenetics. Curr Opin Psychiatry 27:43\u201351","journal-title":"Curr Opin Psychiatry"},{"key":"205_CR36","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.neubiorev.2017.05.029","volume":"80","author":"VM Sinopoli","year":"2017","unstructured":"Sinopoli VM, Burton CL, Kronenberg S, Arnold PD (2017) A review of the role of serotonin system genes in obsessive-compulsive disorder. Neurosci Biobehav Rev 80:372\u2013381","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"205_CR712","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0924-9338(03)00066-X","volume":"18","author":"S Tot","year":"2003","unstructured":"Tot S, Erdal ME, Yazici K, Yazici AE, Metin O (2003) T102C and -1438 G\/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder. Eur Psychiatry 18(5):249\u2013254","journal-title":"Eur Psychiatry"},{"issue":"1","key":"205_CR713","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13651500902903016","volume":"13","author":"FC Van Nieuverburge","year":"2009","unstructured":"Van Nieuverburge FC, Denys DA, Westenberg HG, Deforce DL (2009) Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract 13(1):345\u2013348","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"4","key":"205_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ajp.2013.03.003","volume":"6","author":"B Viswanath","year":"2013","unstructured":"Viswanath B, Taj MJRJ, Purushottam M, Kandavel T, Shetty PH, Reddy YC, Jain S (2013) No association between DRD4 gene and SRI treatment response in obsessive-compulsive disorder: need for a novel approach. Asian J Psychiatr 6(4):347\u2013348","journal-title":"Asian J Psychiatr"},{"issue":"4","key":"205_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/13651501.2011.653375","volume":"16","author":"NC Vulink","year":"2012","unstructured":"Vulink NC, Westenberg HG, van Nieuwerburgh F, Deforce D, Fluitman SB, Meinardi JS, Denys D (2012) Catechol-O-methyltransferase gene expression is associated with response to citalopram in obsessive-compulsive disorder. Int J Psychiatry Clin Pract 16(4):277\u2013283","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"4","key":"205_CR41","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.pbb.2011.10.007","volume":"100","author":"K Wu","year":"2012","unstructured":"Wu K, Hanna GL, Rosenberg DR, Arnold PD (2012) The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 100(4):726\u2013735","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"205_CR42","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2217\/pgs.14.83","volume":"15","author":"G Zai","year":"2014","unstructured":"Zai G, Brandl EJ, M\u00fcller DJ, Richter MA, Kennedy JL (2014) Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics 15(8):1147\u20131157","journal-title":"Pharmacogenomics"},{"issue":"5","key":"205_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/YPG.0000000000000230","volume":"29","author":"G Zai","year":"2019","unstructured":"Zai G, Barta C, Cath D, Eapen V, Geller D, Gr\u00fcnblatt E (2019) New insights and perspectives on the genetics of obsessive-compulsive disorder. Psychiatr Genet 29(5):142\u2013151","journal-title":"Psychiatr Genet"},{"issue":"5","key":"205_CR714","first-page":"479","volume":"21","author":"L Zhang","year":"2004","unstructured":"Zhang L, Liu X, Li T, Yang Y, Hu X, Collier D (2004) Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21(5):479\u2013481","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"}],"container-title":["Current Topics in Behavioral Neurosciences","The Neurobiology and Treatment of OCD: Accelerating Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2020_205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T18:59:45Z","timestamp":1671130785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2020_205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030753924","9783030753931"],"references-count":54,"URL":"https:\/\/doi.org\/10.1007\/7854_2020_205","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"7 February 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}